Press Releases 2021 2020 2019 all January 20, 2021 Dyne Therapeutics Announces Pricing of $168 Million Public Offering January 10, 2021 Dyne Therapeutics Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Study January 5, 2021 Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
